B. Riley Reiterates $21.00 Price Target for AMAG Pharmaceuticals (AMAG)

B. Riley set a $21.00 target price on AMAG Pharmaceuticals (NASDAQ:AMAG) in a research report sent to investors on Wednesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

AMAG has been the subject of several other research reports. Deutsche Bank set a $23.00 target price on shares of AMAG Pharmaceuticals and gave the company a hold rating in a research note on Thursday, September 20th. Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a hold rating to a strong sell rating in a report on Friday, October 5th. Cantor Fitzgerald set a $18.00 price target on shares of AMAG Pharmaceuticals and gave the company a hold rating in a report on Wednesday, September 26th. BidaskClub raised shares of AMAG Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, October 17th. Finally, ValuEngine raised shares of AMAG Pharmaceuticals from a buy rating to a strong-buy rating in a report on Wednesday, October 3rd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. AMAG Pharmaceuticals has a consensus rating of Hold and a consensus price target of $20.97.

AMAG stock opened at $17.05 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.86 and a quick ratio of 2.72. AMAG Pharmaceuticals has a 1-year low of $11.95 and a 1-year high of $26.10. The firm has a market cap of $581.23 million, a price-to-earnings ratio of -2.99 and a beta of 0.48.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($1.11). AMAG Pharmaceuticals had a negative net margin of 6.98% and a negative return on equity of 13.65%. The business had revenue of $122.20 million for the quarter, compared to the consensus estimate of $118.23 million. During the same quarter in the previous year, the firm earned ($4.31) EPS. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. Equities research analysts predict that AMAG Pharmaceuticals will post -2.07 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. Advisors Asset Management Inc. lifted its holdings in AMAG Pharmaceuticals by 791.6% in the second quarter. Advisors Asset Management Inc. now owns 58,970 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 52,356 shares during the period. Tower Research Capital LLC TRC acquired a new stake in AMAG Pharmaceuticals in the third quarter worth about $173,000. HighPoint Advisor Group LLC acquired a new stake in AMAG Pharmaceuticals in the third quarter worth about $188,000. Virtu Financial LLC acquired a new stake in AMAG Pharmaceuticals in the fourth quarter worth about $217,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in AMAG Pharmaceuticals in the third quarter worth about $279,000.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Recommended Story: How much can an individual set aside as a catch-up contribution?

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit